We surly do not need a carnival barking pitchman expounding how great a drug we have, but with that being said, I feel a knowledge and much more dynamic CEO is in order. Keep Jack on the team, but behind the curtain.
Odd their going for EMA before FDA approval.
Actelion submits MAA for pulmonary hypertension drug • 3:36 PM
Douglas W. House, SA News Ed...
Actelion Ltd (OTCPK:ALIOF) (OTC:ALIOY) submits a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for Uptravi (selexipag) for the treatment of patients with pulmonary arterial hypertension (PAH).
Selexipag is selective IP prostacyclin receptor agonist. Prostacyclin activates the IP receptor inducing vasodilation and inhibiting proliferation of vascular smooth muscle cells. If approved, it will be the first such drug cleared for use in PAH.
In April 2008, the company signed a license agreement with Nippon Shinyaku under which Actelion has global development and commercialization rights to selexipag outside of Japan. The firms will be partners in Japan.
Actelion plans to submit an NDA to the FDA shortly.
I wouldn't say Uh Oh just yet. A Co. the size of Nestle interested in weight loss does show there are big $'s to be made in the battle for obesity treatment however. It's all good!
"AMPK has been known about for many years. The trick that no one has mastered has been how to effectively activate AMPK. Nestle has not even begun clinical trials yet, so it may be a few years or more before you can drink your way to weight loss."
It was a sunny Sunday morning, and golf.paul123 was beginning his preshot routine, visualizing his upcoming shot, when a voice came over the clubhouse loudspeaker. "Would the gentleman on the ladies' tee please back up to the men's tee."
golf.paul123 remained in his routine, seemingly unfazed by the interruption.
A little louder: "Would the man on the women's tee kindly back up to the men's tee!"
golf.paul123 raised up out of his stance, lowered his driver, and shouted, "Would the announcer in the clubhouse kindly shut up and let me play my second shot?"
Federal employees will start being covered for obesity treatments and meds. come January. We should see some increase in scripts from this, I'd say in early March.? Should go nicely hand in hand with seasonality uptick.
Knowledge of C-31's existence, and awareness of Cessium-131's benefits in a miriad of cancer treatments is the point of the spear in achieving the companies goals. Soon to be standard of care item in the battle on Cancer. IMO......
"Clinical evidence provided through protocols performed by major medical centers that prove utilizing Cesium-131 is either equal to or better than the current standard of care alternatives, together with patients enjoying an improved quality of life, remains the key to IsoRays success. These studies also aid in generating awareness and ultimately general adoption by community hospitals/physicians which will drive consumers to our product offerings. To this end and given this growing acceptance and interest in our now published results, we remain committed to our strategic sales and marketing objectives, which we believe will contribute to long term growth and achieving profitability."
Sentiment: Strong Buy
I don't think it's to much ask at all. Great way to "kick off" the new diet season in January. Something really upbeat, with some real world success stories perhaps. Anything that grabs the viewer's attention!
All in all, this obviously has been pretty well received by the "Street". And too think, the best is yet to come.
Next catalyst please! ;0)√
Sentiment: Strong Buy
He does have a way of opening the proverbial "can of worms".
Guess there is no sense in dissecting a flea here, especially on a Fri. afternoon. Lol
Good luck too you as well!
Statements like this is what. They "may" affect my position. But your right, of course, probably not ;0)
Concerning Smoking Cessation Study:
"The essence here is that this first study appears to be a wash of sorts. It means that 2014 is essentially gone and we could lose a big chunk of 2015 getting to where we hoped we would already be. Instead of moving forward to phase III trials in the next few months a second phase II study is a distinct possibility. Had the results of the first study not raised so many questions, we could be seeing the company seek a label change at the close of next year. Instead, it may be the end of 2016 before this event can happen. The dollars and time invested thus far are not totally wasted. The results were compelling enough to figure out the next step. The bottom line is that these smoking results are a step forward in the sense of progressing forward, but a step back in how the street assigns value to Arena and when that values is assigned."
I'll be waiting with baited breath for your next well informed and meaningful post. Oh wait, there won't be a next one, as you have never posted the first one yet.
Anything that effects pps, or gives insight, even from the short side, is of interest to me. Hearing of him does get old, but he is informed. Slanted of course, but informed.
Yet he comes out with another mostly pessimistic article Belviq and Smoking Cessation, Sizzle or Smolder. Cup ALWAYS half empty for this guy. I'd rather he go short so his readers no the real side of the fence he's on. Grrr.....